Sage Therapeutics Inc.

07/24/2024 | Press release | Distributed by Public on 07/24/2024 05:18

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.